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Why was the cohort set up?
Globally, cervical cancer is the fourth most common can-
cer among women, with an estimated 528 000 new cases
in 2012.1 Although it remains a significant public health
problem worldwide, the burden of cervical cancer falls dis-
proportionately on low-resource countries. In the USA, the
incidence rate of cervical cancer was 6.6 per 100 000 in
2012,1 compared with 23.0 per 100 000 in Nigeria2 which
had about half the population of the USA in 2012.
Persistent high-risk human papillomavirus (hrHPV)
infection of the cervix is a necessary cause of cervical can-
cer.3,4 About 80% of sexually active individuals become
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Cohort Profile
infected with at least one genital hrHPV in their lifetime.
Most of the infections are cleared, but about 10% become
persistent infections.5–7 The mechanism by which some in-
dividuals are able to remain uninfected while some clear
the infection and others remain persistently infected,
remains unclear. Of the women with persistent hrHPV in-
fection, only  12% go on to develop cervical intraepithe-
lial neoplasia (CIN)2,3 and cervical cancer.8 Therefore,
several co-factors are required to support the cervical car-
cinogenesis induced by persistent hrHPV infection.7,9
Data from Western series suggest that HPV types 16
and 18 account for most of the cases of cervical cancer in
those environments.4 However, there have been few longi-
tudinal studies of hrHPV infections and their association
with cervical cancer in much of the rest of the world.
Given the marked heterogeneity of types and prevalence of
multiple hrHPV infection in many parts of the developing
world, variation in ability of different hrHPV types to es-
tablish persistent infection and concerns about the cover-
age of existing vaccines, longitudinal studies of large
numbers of women in the general population in different
regions of the world, with information on HPV types and
risk factors, are critical to bridging the knowledge gaps, es-
pecially in African populations where such studies are
scarce.10–14
The aetiology of cervical cancer is multifactorial. It is
clear that environmental risk factors such as smoking, age
at first sexual intercourse, age at first full-term pregnancy,
high parity and use of oral contraceptives which have been
implicated in persistent hrHPV infection, do not completely
explain the association between hrHPV infection and cer-
vical cancer, and several studies have identified a role for
genetics and heritability in its aetiology.15–23 These studies
suggest that genetic factors contribute to the risk of persist-
ent hrHPV infection and progression to cervical cancer. A
recent review of 15 studies on heritability of cervical cancer
risk suggested that having a first-degree relative with cer-
vical cancer increases an individual’s risk by 1- or 2-fold.24
Other reviews concluded that there is a potential role for
genetic factors in cervical cancer in situ and estimated the
heritability to be between 11% and 15%.25–27 Nevertheless,
there have been few studies of genetic risks of the different
components of the pathway to cervical carcinogenesis
among all populations, particularly in Africans.
An important yet understudied aspect of HPV carcino-
genesis is the role of innate immunity and emerging know-
ledge about the vaginal microbiome, and the role that
these play in cervical carcinogenesis.28–34 Vaginal micro-
biota may affect the risk of persistent hrHPV infection
through rich, complex, dynamic and individual-specific
microbial interaction with the host such as through signal-
ling of host cells that affect inflammatory, immunological,
and host-defence functions.35,36 Specific types of vaginal
microbiota may sculpt the cervical cytokines in ways that
influence the persistence of HPV infection or breach the in-
cipient latency of the persistent hrHPV infection state and
drive it towards induction of malignancy in the cervix.35
Furthermore, health behaviours, including intravaginal
health practice, number of sexual partners and other fac-
tors, may affect the types of vaginal microbiota and their
association with risk of persistent hrHPV infection. There
have been few studies of the vaginal microbiota37,38 and
the interaction between the vaginal microbiota and cervical
cytokines and their association with persistent hrHPV
infection.27,28
The design of the African Collaborative Center for
Microbiome and Genomics Research (ACCME) HPV and
Cervical Cancer Cohort Study enables us to study environ-
mental, microbiomic, genetic and epigenetic factors associ-
ated with persistent hrHPV infection, in order to improve
knowledge of the mechanism of HPV carcinogenesis and
discover biomarkers of persistent hrHPV infection and cer-
vical cancer. We evaluate the epidemiological determinants
of persistent infection, and the genetic and epigenetic
changes in hrHPV as well as in somatic cervical cells and
their association with persistent hrHPV infection and
CIN2þ. We evaluate the epidemiological determinants of
patterns of cervical cytokines and their association with
persistent hrHPV infection. We identify the community
state types and stability of the vaginal microbiota, and
their association with persistent hrHPV infection. We con-
duct genome-wide association studies (GWAS) to identify
the genetic variants associated with the risk of persistent
hrHPV infection and CIN2þ.
The ACCME cohort is located in Nigeria. Ethical ap-
proval to conduct this study was obtained from the
National Health Research Ethics Committee in Nigeria.
All study participants were informed about the study and
were requested to consent before participation. The in-
formed consent is reiterated at different study visits and
new consent is obtained for specific components of the re-
search project. An ethics and regulatory affairs coordinator
conducts regular audits of the informed consent process
and evaluates the understanding of the informed consent
among randomly selected study participants. This study is
funded by the National Institutes of Health.
Who is in the cohort?
There are 36 states, six geopolitical zones and a Federal
Capital Territory in Nigeria. Our study is located in Abuja,
the main municipality in the Federal Capital Territory,
which is located in the centre of the country. In general,
the socio-demographic characteristics of women in Abuja,
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North Central Nigeria, were similar to those of women in
the South East, South South, and South West zones in
2013, but not the North East or North West which are
more rural and the women there are less likely to be edu-
cated or employed.39 We randomly selected seven out of
42 districts in Abuja for our study. The populations served
by these study sites varied from urban city dwellers to
semi-rural to rural people living on farmlands and villages.
In each district, we employed extensive community engage-
ment strategies, to create awareness of the study and en-
sure that a representative sample of the target population
was enrolled. These strategies included: focus group dis-
cussions and surveys to identify cultural issues, literacy lev-
els and local language; town hall meetings and community
forums to gain input from the general public; participatory
evaluation; and partnerships with community stakeholders
to create alliances and ownership and build trust. We also
created awareness of the study through the use of: mass
media including radio and television talk shows; social
media including Twitter and Facebook; interactions with
key opinion leaders; and engagement of religious leaders,
women’s advocacy groups, corporate organizations, the
Nigerian Federal Ministry of Health and community
members.
In this study, we identified women who were at least 18
years old, had had sexual intercourse and had no previous
history of cervical abnormalities, cervical cancer or total
abdominal hysterectomy, by area sampling in Abuja.
Potential participants were offered HIV testing with volun-
tary counselling. Those who were HIV-positive were not
eligible to participate in the cohort and were referred to
free HIV treatment programmes. Enrolment into the co-
hort began in February 2014 in Abuja, Central Nigeria.
How often is follow-up?
Data are collected during the initial visit and at 6, 12, 18
and 24 months. Research nurses collect epidemiological
data using our tablet computer-assisted survey instruments
(TaCASI) directly into a secure web database applica-
tion—the Research Electronic Data Capture (REDCap)
platform hosted at the Institute of Human Virology
(IHVN).43 Paper copies of the study forms are available to
serve as backup for data collection. Detailed contact infor-
mation (address and phone numbers) are collected from all
participants. Follow-up visits are scheduled at appropriate
times and reminders are sent by text messages, e-mails and
phone calls. Where participants cannot be reached by
phone, home visits are conducted.
What is being measured?
The data collection tools were piloted in a study of 1000
women with similar characteristics as the participants of
the ACCME study. In order to compute socioeconomic
status (SES) in a low-resource environment where in-
come data are sparse, we generated wealth index data as
previously described.44 In summary, we used principal
components analysis (PCA) with varimax rotation to com-
pute factor scores based on the sum of the ownership of
household items weighted by their factor loading. We
sorted the data on the first principal component which had
the highest eigen value, and divided all respondents into
three categories based on its value. Participants with the
lowest 40% were categorized as low SES, the middle 40%
were categorized as middle SES and the top 20% were
categorized as high SES. The validity and reproducibility
of the wealth index has been examined in previous studies
and it correlates well with other measures of wealth in en-
vironments without reliable expenditure data.44
We adapted tools for the measurement of alcohol in-
take, cigarette smoking, tobacco use, sexual and repro-
ductive health and medical and drug history from the
PhenX toolkit version of 20 September 2013, version
5.6.45 We obtained self-report of occurrence of diseases
such as cancer, diabetes, myocardial infarction and stroke.
We modified the Harvard School of Public Health’s
Nurses’ Health Study II physical activity questionnaire to
collect data on physical activity and we used the Nigerian
food frequency questionnaire that we had previously de-
veloped to collect information on dietary intake. Members
of the ACCME research group have used these tools for
previous research in Africa.46–48 We asked participants
about their sexual activities in the past 24 h including his-
tory of sexual intercourse (vaginal, anal, oral), use of
contraceptives, sex toys and lubricants, and vaginal symp-
toms. Given the sensitive nature of some questions, espe-
cially those on sexual history, we ensured the mode and
placement of the questions were appropriate, the inter-
viewers were trained to be culturally and morally sensitive
and each interview was conducted in a relaxed, private set-
ting, sufficiently so to encourage accurate responses.
Three blood pressure (BP) measurements are taken at
least 1 min apart in accordance with the American Heart
Association recommendations,49 using the automated
OMRONV
R
BP760 (HEM-7220-Z) with patients in a sitting
position, not earlier than 15 min after participant arrival
at the study site. Standing height, body weight and waist
and hip circumferences were measured in accord-
ance with the World Health Organization (WHO)
Multinational Monitoring of Trends in Cardiovascular
Disease (MONICA) project.50 Pelvic examinations were
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performed on all participants and data on any significant
findings in the lower abdomen, the vulva/perineum, va-
gina, cervix and adnexa were collected as described.51,52
We performed bivalve speculum examination and meas-
ured the vaginal pH using pH paper (pHydrionV
R
, Micro
Essentials Laboratories, Brooklyn, NY) and compared col-
our change of the pH paper with the manufacturer-
provided colour charts.53,54 All research nurses passed a
colour perception test before performing the pH tests.
The data collected by questionnaires and during the
Clinical Evaluation, Sample Evaluation and Testing sched-
ule are outlined in Supplementary Table 1 (available as
Supplementary data at IJE online).
Biological samples including blood and mid-vaginal and
ectocervical cell samples are collected at baseline and dur-
ing follow-up visits. The blood samples are separated into
plasma, serum, buffy coat, red blood cells and clot. All bio-
logical samples are stored at -80 C at the ACCME
Laboratories, IHVN, Abuja, Nigeria. Germline, somatic
and viral DNAs are extracted using MagNa Pure LC 2.0V
R
and Qiagen Qiacube HT robotic nucleic acid isolation and
purification platforms. Germline DNA is quantitated using
NanoDrop 8000 UV-Vis spectrophotometer at wave-
lengths of 260 and 280 nm, after which working dilutions
to the 5–10 ng of DNA required per reaction are created.
Cervical exfoliated samples are analysed for any HPV
and hrHPV using SPF10 PCR-DEIA-LiPA25, version 1, ac-
cording to manufacturer’s instructions. Samples of cervical
cytokines are collected and stored immediately in ice cool-
ers and transported to the laboratory for storage. Cervical
cytokines are measured using polystyrene non-magnetic






CA). The vaginal microbial species composition and abun-
dance will be determined as described by Forney et al.30
The V1-V3 hypervariable regions of the 16S rRNA genes
will be amplified using an optimized primer set 27F and
533R as recommended by the Human Microbiome Project
(HMP) [http://www.hmpdacc.org]. Colposcopy and biopsy
will be done for all individuals with persistent hrHPV in-
fection and clinical features of a cervical lesion suspected
to be CIN2þ and for matching controls. Biopsy samples
are handled according to the TCGA [http://cancergenome.
nih.gov)] standard operating procedure. Spot urine sam-
ples are collected and tested for glucose, ketones, specific
gravity, blood, pH, protein, nitrites and leukocytes with
MultistixV
R
10 SG reagent strip; the rest are stored in the
laboratory at -80 C. Women with cervical cancer are biop-
sied and referred for appropriate treatment. We store fresh
frozen samples and paraffin embedded samples of the cer-
vical biopsy and collect minimal data from these women;
they are not enrolled in the prospective cohort.
Quality assurance and control
Data
Tablet computer-assisted survey instruments (TaCASI)
have proved versatile in survey research that incorporates
sensitive questions like those on sexual behaviour.55–57 We
use real-time data entry into secure RedCap databases with
in-built logic and error checks, which enables data man-
agers to review data and follow-up on missing values and
outliers with site research associates promptly.11,12,55–59
Laboratory
Two independent pathologists who are blinded to the HPV
status of the participants report on the histological diag-
noses. Quality assurance (QA) and quality control (QC) of
HPV genotyping is done in collaboration with DDL diag-
nostic laboratory. Human genomics QA/QC is done in col-
laboration with the Center for Research on Genomics and
Global Health, at the National Human Genome Research
Institute. We store digital colposcopy images on a private
cloud server for secondary review.
What has been found?
The focus of this project so far has been on establishing the
study population and obtaining baseline data on known
and potential risk factors of hrHPV infection and CIN2þ,
which will be used for epidemiological and genomic stud-
ies. Some early results are presented here.
From commencement of enrolment in February 2014 to
July 2016, 11 500 women had been enrolled in the
ACCME cohort. The women in this cohort have homoge-
neous contraceptive, sexual and reproductive charac-
teristics and health status compared with similarly aged
HIV-negative women, in the general population.40–42
Many of the women enrolled were in their third or fourth
decade of life, the mean age [standard deviation (SD)] of
the participants was 39 (10) years. Most of the participants
were married (77%; 8832/11 500), monogamous and live
with their spouses (86%; 7556/8832). Many participants
have had some university education (45%; 5152/11 500)
and have professional jobs (36%; 4175/11 500). Selected
socio-demographic characteristics of the study participants
at baseline are shown in Table 1. To date we have tested
the baseline samples of all the study participants for HPV
using DEIA, and observed that 42% (4773/11 500) tested
positive (Table 2). Similar tests for HPV have been done in
5349 participants at the 12 months follow-up visit, and we
observed that 21% (1107/5349) of these women had per-
sistent HPV infections. About 16% of the study partici-
pants have had oral sex and < 1% have had anal sex
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(Table 3). Most participants thought anal sex was un-
acceptable for health (57%), religious (53%) and/or cul-
tural (26%) reasons (multiple responses allowed). Some of
the participants reported a history of physician-diagnosed
hypertension (15%), diabetes (2%), hypercholesterolaemia
(4%) or heart disease (0.3%) (Table 4). We found the
mean (SD) vaginal pH was 5.2 (0.5); it was similar among
HPV-positive and HPV-negative women. Selected
Table 1. Selected baseline socio-demographic characteristics of women in the ACCME Cohort, n (%)
Characteristics Total Rural Semi-rural Urban
n ¼ 11500 n ¼ 1380 n ¼ 5336 n ¼ 4784
Age, yearsa 38.8 (9.6) 38.4 (9.9) 37.8 (9.7) 40.1 (9.2)
Age categories, years
18–29 2093 (18.2) 304 (22.0) 1180 (22.1) 609 (12.7)
30–39 4105 (35.7) 462 (33.5) 1926 (36.1) 1717 (36.0)
40–49 3530 (30.7) 398 (28.8) 1494 (28.0) 1638 (34.2)
50–59 1576 (13.7) 186 (13.5) 656 (12.3) 734 (15.3)
 60 196 (1.7) 30 (2.2) 80 (1.5) 86 (1.8)
Tribe
Hausa 862 (7.5) 79 (5.7) 598 (11.2) 185 (3.8)
Ibo 2531 (22.0) 195 (14.1) 875 (16.4) 1461 (20.5)
Yoruba 1322 (11.5) 59 (4.3) 464 (8.7) 799 (16.7)
Other tribes 6785 (59.0) 1047 (75.9) 3399 (63.7) 2339 (50.0)
Religion
Atheist 23 (0.2) 2 (0.1) 11 (0.2) 10 (0.2)
Christian 9545 (83.0) 1208 (87.5) 4173 (78.2) 4164 (87.0)
Eckankar 2 (0.02) 0 (0.0) 0 (0.0) 2 (0.04)
Judaism 2 (0.02) 0 (0.0) 1 (0.01) 1 (0.02)
Muslim 1920 (16.7) 168 (12.2) 1147 (21.5) 605 (12.7)
Traditional 8 (0.07) 2 (0.1) 4 (0.1) 2 (0.04)
Marital status
Cohabiting 23 (0.2) 8 (0.6) 11 (0.2) 4 (0.1)
Divorced/separated 310 (2.7) 33 (2.4) 112 (2.1) 165 (3.4)
Married 8832 (76.8) 1070 (77.5) 4204 (78.8) 3558 (74.4)
Single 1668 (14.5) 148 (10.7) 710 (13.3) 810 (17.0)
Widowed 667 (5.8) 121 (8.8) 299 (5.6) 247 (5.1)
Marital arrangement
Monogamous (live separately) 386 (4.4) 56 (5.2) 131 (3.1) 199 (5.5)
Monogamous (live together) 7556 (85.6) 913 (84.4) 3529 (85.3) 3114 (86.6)
Polygamous (all live together) 628 (7.1) 84 (7.8) 380 (8.9) 164 (4.6)
Polygamous (live separately) 262 (2.9) 28 (2.6) 114 (2.7) 120 (3.3)
Education
No formal schooling 1127 (9.8) 251 (18.2) 779 (14.6) 97 (2.0)
Primary 1069 (9.3) 277 (20.1) 598 (11.2) 194 (4.0)
Secondary 2507 (21.8) 486 (35.2) 1409 (26.4) 612 (12.8)
University 5152 (44.8) 309 (22.4) 2065 (38.7) 2778 (58.1)
Postgraduate 1645 (14.3) 57 (4.1) 485 (9.1) 1103 (23.1)
Occupation
Professional 4175 (36.3) 208 (15.1) 1484 (27.8) 2483 (51.9)
Self-employed 3634 (31.6) 567 (41.1) 1920 (36.0) 1147 (24.0)
Manual 678 (5.9) 195 (14.1) 368 (6.9) 115 (2.4)
Skilled manual 897 (7.8) 149 (10.8) 507 (9.5) 241 (5.0)
Student 747 (6.5) 70 (5.1) 438 (8.2) 239 (5.0)
Unemployed 1369 (11.9) 191 (13.8) 619 (11.6) 559 (11.7)
Socioeconomic status
Low 4600 (40.0) 927 (67.2) 2759 (51.7) 914 (19.1)
Middle 4715 (41.0) 373 (27.0) 1969 (36.9) 2373 (49.6)
High 2185 (19.0) 80 (5.8) 608 (11.4) 1497 (31.3)
aMean (standard deviation).
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Table 2. Prevalence (%) of HPV infection among women in the ACCME cohort
Persistently DEIA HPV-positive
HPV status Any HPVa Low-risk HPVb High-risk HPVþ
HPV-positive at baseline 4773 (41.5) 1718 (36.0) 3050 (63.9)
HPV-positive at follow-up visitc 2305 (43.1) 521 (22.6) 1784 (77.4)
Persistent HPV-positive 1107 (20.7) 139 (12.6) 598 (54.0)
aBased on DEIA.
bResults based on LiPA.
cFollow-up visit at 12 months after baseline, current total n ¼ 5349.
Table 3. Some baseline sexual and reproductive history of women in the ACCME cohort
Characteristics Total HPV-negative HPV-positive
n ¼ 11500 n ¼ 6727 n ¼ 4773
Mean (standard deviation)
Age at menarche 14 (2) 14 (2) 14 (2)
Age at menopause 44 (9) 44 (9) 43 (9)
Age at first vaginal sexual intercourse 20 (4) 21 (4) 20 (4)
Age at first oral sexual intercourse 26 (6) 27 (6) 26 (6)
Age at first anal sexual intercourse 27 (7) 27 (7) 26 (7)
Number of lifetime sexual partners
Vaginal 2.6 (2.6) 2.7 (2.6) 2.8 (2.7)
Oral 1.8 (1.7) 1.6 (1.5) 1.8 (1.8)
Anal 1.3 (1.2) 1.0 (0.6) 1.3 (1.2)
n (%)
Types of sexual experiencea
Vaginal 11500 (100.0) 6727 (100.0) 4773 (100.0)
Oral 1832 (15.9) 1016 (15.1) 816 (17.1)
Anal 69 (0.6) 42 (0.6) 27 (0.6)
First type of sexual experience
Vaginal 9574 (98.3) 5605 (98.4) 3969 (98.1)
Oral 154 (1.6) 8 (1.5) 3 (1.8)
Anal 11 (0.1) 82 (0.1) 72 (0.1)
Oral sex typea
Fellatio 964 (58.2) 545 (59.3) 419 (56.8)
Cunnilingus 689 (41.6) 371 (40.4) 318 (43.1)
Anallingus 4 (0.2) 3 (0.3) 1 (0.1)
Anal sex typea
Receptive 195 (94.4) 109 (55.9) 86 (44.1)
Insertive (using objects e.g. sex toys) 1 (0.5) 0 (0.0) 1 (100.0)
Both 9 (5.1) 6 (66.7) 3 (33.3)
Sexual type preferred
None 75 (0.8) 52 (0.9) 23 (0.6)
Vaginal 9363 (97.3) 5484 (97.2) 3879 (96.9)
Oral 14 (2.0) 9 (1.7) 5 (2.4)
Anal 196 (0.2) 99 (0.2) 97 (0.1)
Usual frequency of sexual intercourse
Vaginal
< 1/month 3186 (32.5) 1826 (32.0) 1342 (33.2)
1–3/month 1825 (18.7) 1010 (17.7) 815 (20.2)
1/week 2339 (24.0) 1410 (24.7) 929 (23.0)
2–4/week 2075 (21.3) 1254 (22.0) 821 (20.3)
 5/week 335 (3.5) 202 (3.6) 133 (3.3)
(Continued)
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Table 3. Continued
Characteristics Total HPV-negative HPV-positive
n ¼ 11500 n ¼ 6727 n ¼ 4773
Oral
< 1/month 9208 (95.1) 5392 (95.0) 3816 (95.1)
1–3/month 233 (2.4) 125 (2.2) 108 (2.7)
1/week 101 (1.0) 65 (1.2) 36 (0.9)
2–4/week 105 (1.1) 65 (1.1) 40 (1.0)
 5/week 41 (0.4) 27 (0.5) 14 (0.3)
Anal
< 1/month 9635 (99.6) 5643 (99.6) 3992 (99.6)
1–3/month 25 (0.2) 12 (0.2) 13 (0.3)
1/week 6 (0.05) 3 (0.05) 3 (0.06)
2–4/week 8 (0.07) 7 (0.1) 1 (0.02)
 5/week 4 (0.03) 3 (0.05) 1 (0.02)
Usual gender of sexual partners
Only males, never females 9546 (99.4) 5578 (99.3) 3968 (99.2)
Mostly males, rarely females 54 (0.5) 28 (0.6) 24 (0.7)
Only females, never males 10 (0.1) 5 (0.1) 5 (0.1)
Mostly females, rarely males 7 (1.0) 6 (0.1) 1 (0.1)
Menopausal status
Premenopausal 8049 (82.7) 4704 (82.7) 3345 (82.8)
Postmenopausal 1678 (17.3) 985 (17.3) 693 (17.2)
Ever been pregnant
Yes 8698 (89.1) 5163 (90.4) 3535 (87.3)
No 1061 (10.9) 545 (9.6) 516 (12.7)
aMultiple responses allowed. HPV results are based on DEIA tests at baseline only. Given the sensitive nature of the sexual and reproducibility history ques-
tions, some women did not respond. Therefore the total does not sum up to 11 500.
Table 4. Baseline history of selected physician-diagnosed medical conditions among women in the ACCME cohort, n (%)
Disease Mean age at diagnosis (years) Total (%) Rural (%) Semi-rural (%) Urban (%)
n ¼ 11500 n ¼ 1380 n ¼ 5336 n ¼ 4784
Hypertension
Yes 40 (8) 1702 (14.8) 187 (13.5) 630 (11.8) 885 (18.5)
No – 9798 (85.2) 1193 (86.5) 4706 (88.2) 3899 (81.5)
Diabetes
Yes 43 (8) 219 (1.9) 21 (1.5) 69 (1.3) 129 (2.7)
No – 11281 (98.1) 1359 (98.5) 5267 (98.7) 4655 (97.3)
Hypercholesterolaemia
Yes 43 (8) 552 (4.1) 108 (7.8) 133 (2.5) 311 (6.5)
No – 10948 (95.2) 1272 (92.2) 5203 (97.5) 4473 (93.5)
Rheumatic fever
Yes 39 (10) 58 (0.5) 23 (1.7) 21 (0.4) 14 (0.3)
No – 11442 (99.5) 1357 (98.3) 5315 (99.6) 4770 (99.7)
Heart disease
Yes 40 (10) 35 (0.3) 0 (0.0) 11 (0.2) 24 (0.5)
No – 11465 (99.7) 1380 (99.8) 5325 (99.8) 4760 (99.5)
TIA/stroke
Yes 42 (9) 35 (0.3) 5 (0.4) 16 (0.3) 14 (0.3)
No – 11465 (99.7) 1375 (99.6) 5320 (99.7) 4770 (99.7)
Kidney disease
Yes 45 (9) 46 (0.4) 6 (0.4) 11 (0.2) 29 (0.6)
No 11454 (99.6) 1374 (99.6) 5325 (99.8) 4755 (99.4)
Cancer
Yes 41 (10) 23 (0.2) 7 (0.5) 6 (1.1) 10 (1.2)
No – 11477 (99.8) 1373 (99.5) 5330 (99.9) 4774 (99.8)
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gynaecological characteristics of the study participants at
baseline are shown in Table 5. Our results on sexual health
and behaviour provide important data for studies of associ-
ations between these characteristics and HPV-associated
cancers including cervical, head and neck, and anal cancers,
and identifies attitudes and beliefs which may contribute to
the social epidemiological risk for other non-communicable
diseases (NCD). The study attrition rate is  20%.
Training and capacity development
The ACCME project includes a training programme in epi-
demiology, molecular biology, data management and analysis.
Several pre- and postdoctoral trainees are currently engaged in
the project and are taking the lead in several analyses and pub-
lications. Students and faculty members from Nigerian and
US universities and research institutes have also used the re-
sources of the project for their own research projects.
Future plans?
We will contribute DNA samples from our study participants
to the H3Africa Biorepositories according to the H3Africa
guidelines. We are participating in the development of the
H3Africa Consortium Genome Analysis Array chip in collab-
oration with other H3Africa projects and Illumina Inc. The
resultant chip will be highly informative for genomics re-
search in African populations. We plan to replicate our
genomics findings in other African cohorts. The combination
of somatic and germline mutation analyses in our study en-
hances opportunities for gene discovery, understanding of
gene functions, new clinical insights and integrative analysis
of cervical cancer. Our research will also characterize the epi-
demiology of HPV infection in Nigeria before widespread de-
ployment of HPV vaccination. We intend to maintain and
expand this valuable cohort to include male partners of the
participants and to study other NCDs in future.
What are the main strengths and
weaknesses?
The ACCME cohort incorporates a large number of repeated
measurements of a wide range of exposures. There are also
strong data and laboratory QA/QC procedures in collabor-
ation with local and international researchers incorporated
into the project, thereby ensuring high quality of the data.
An ethics and regulatory compliance officer independently
monitors research activities at clinical sites and generates re-
ports for the Study leadership for action. Close collaboration
with the NIH-funded West African Bioethics Training
Program [http://bioethicscenter.net)] ensures ongoing train-
ing in research ethics, good clinical and laboratory practices,
and responsible conduct of research. We implement exten-
sive community engagement efforts that include: community
rallies; regular meetings with research participants; circula-
tion of study newsletters that provide updates about study
Table 5. Selected baseline gynaecological characteristics of women in the ACCME Cohort, n (%)
Gynaecological characteristics Total HPV-negative HPV-positive
n ¼ 11500 n ¼ 6727 n ¼ 4773
Vaginal pHa 5.2 (0.5) 5.2 (0.5) 5.2 (0.6)
Ectopy observed
Yes 1368 (11.9) 809 (12.0) 559 (11.7)
No 10132 (88.1) 5918 (88.0) 4214 (88.3)
Transformation zone
< 25% 3324 (28.9) 1978 (29.4) 1346 (28.2)
25–50% 4310 (37.5) 2382 (35.4) 1928 (40.4)
51–75% 2901 (25.2) 1823 (27.1) 1078 (22.6)
> 75% 965 (8.4) 544 (8.1) 421 (8.8)
Squamo-columnar junction
Fully observed 8245 (71.7) 4877 (72.5) 3368 (71.1)
Partially observed 2369 (20.6) 1406 (20.9) 963 (20.1)
Not observed 886 (7.7) 444 (6.6) 422 (8.8)
Cervical friabilityb
None 10568 (91.9) 6168 (91.7) 4400 (92.2)
Mild 839 (7.3) 511 (7.6) 328 (6.9)
Moderate 93 (0.8) 48 (0.7) 45 (0.9)
HPV status based on DNA enzyme immunoassay (DEIA) test.
aMean (standard deviation).
bCervical friability: mild, discrete spot of blood on swab; moderate, pink discolouration, swab soaked.
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progress and challenges; and motivational and health educa-
tion messages through e-mails, radio, TV and newspapers.
The study maintains a webpage, a Facebook page and an ac-
tive Twitter account. Study participants are able to contact
the research staff and leadership via phone applications,
including Blackberry messenger and WhatsApp.
A major limitation of longitudinal studies is loss to
follow-up. This can be particularly challenging in low-re-
source environments where participants have poor history
of follow-up even in clinical care. To improve participant
retention in the cohort, we deployed several strategies
including extensive use of mobile health-based interven-
tions such as automated phone applications that are used
to send health tips and visit reminders to participants be-
fore their scheduled appointment, regularly. Thus, we have
achieved a participant retention rate of 80%.
Problems associated with conducting research in re-
source-limited settings that may affect ACCME include
poor infrastructure, inadequate power supply, challenges
with conduct of research in low-literacy environments and
lack of trained personnel. To address these, we: purchased
state of the art laboratory equipment with service agree-
ments for genomic analyses; set up a three-level power
backup system with multiple power generators, inverters
and batteries for the laboratory; develop appropriate
health education materials; train and re-train all research
staff; and implement schemes for motivation of staff
through regular research meetings and opportunities to at-
tend international meetings, implementation of mentored
research projects and generation of appropriate health edu-
cation materials. All of these challenges have contributed
to much higher cost for implementation of this research
than anticipated. Nonetheless, we collaborate with re-
nowned international institutions in the USA, UK and The
Netherlands for ongoing staff training and support.
Can I get hold of the data? Where can I find
out more?
Further information is available at [http://h3africa.org/].
Documentation for the ACCME cohort including the ques-
tionnaires, information sent to the participants and detailed
information about the research, is available at [http://
h3accme.com/. We also welcome specific queries and pro-
posals for collaboration, which should be directed to the sci-




Supplementary data are available at IJE online.
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